Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigating the Safety, Feasibility, and Optimal Dose of Fluorescently Labeled Adalimumab-680LT for Visualizing Drug Targeting in Inflammatory Bowel Diseases

NCT06117423 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT06117423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06117423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigating the Safety, Feasibility, and Optimal Dose of Fluorescently Labeled Adalimumab-680LT for Visualizing Drug Targeting in Inflammatory Bowel Diseases
Lead sponsor
University Medical Center Groningen
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 31, 2024
Completion date
June 30, 2025
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease, ulcerative colitis